Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Items 901–1,000 of 1,002
Jiang, Z., Cui, W., Prasad, P., Touve, M. A., Gianneschi, N. C., Mager, J., & Thayumanavan, S. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b01321 · Cited by 37
Progress and setbacks: The two faces of technology emergence
Kapoor, R., & Klueter, T. M. (2019) · Research Policy · doi:10.1016/j.respol.2019.103874 · Cited by 37
Microfluidic Based Physical Approaches towards Single-Cell Intracellular Delivery and Analysis
Kaladharan, K., Kumar, A., Gupta, P., Illath, K., Santra, T. S., & Tseng, F. (2021) · Micromachines · doi:10.3390/mi12060631 · Cited by 36
Tay, A. K. P., & Melosh, N. A. (2021) · Small · doi:10.1002/smll.202103198 · Cited by 36
Singh, G., Sikder, A., Phatale, V., Srivastava, S., Singh, S. B., & Khatri, D. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104876 · Cited by 30
Tekie, F. S. M., Atyabi, F., Soleimani, M., Arefian, E., Atashi, A., Kiani, M., Khoshayand, M. R., Amini, M., & Dinarvand, R. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.09.014 · Cited by 36
Evaluation of the effect of vector architecture on DNA condensation and gene transfer efficiency
Canine, B., Wang, Y., & Hatefi, A. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.012 · Cited by 36
“Viruses have evolved to efficiently overcome these barriers; however, safety and toxicity issues have limited their use for systemic gene delivery [4].”
BackgroundNanotechnology for ocular therapeutics and tissue repair
Raju, H. B., & Goldberg, J. L. (2008) · Expert Review of Ophthalmology · doi:10.1586/17469899.3.4.431 · Cited by 36
Baculovirus vectors for antiangiogenesis-based cancer gene therapy
Luo, W.-Y., Shih, Y.-S., Lo, W.-H., Chen, H.-R., Wang, S.-C., Wang, C., Chien, C.-H., Chiang, C.-S., Chuang, Y.-J., & Hu, Y.-C. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.35 · Cited by 36
Use of genome-editing tools to treat sickle cell disease
Tasan, I., Jain, S., & Zhao, H. (2016) · Human Genetics · doi:10.1007/s00439-016-1688-0 · Cited by 36
“…requires utilization of viral vectors for efficient gene delivery and such vectors still hold long-term concerns such as immunogenic response or carcinogenesis due to random insertional mutagenesis (Check 2002; Baum et al. 2003; Thomas et al. 2003; Woods et al. 2006; Hacein-Bey-Abina et al. 2008).”
Fehér, A., Boross, P., Sperka, T., Miklóssy, G., Kádas, J., Bagossi, P., Oroszlan, S. I., Weber, I. T., & Tőzsér, J. (2006) · Journal of General Virology · doi:10.1099/vir.0.81382-0 · Cited by 36
“Furthermore, the majority of the retroviral vectors are based on MLV (Thomas et al., 2003).”
BackgroundKalle, C. V., Fehse, B., Layh‐Schmitt, G., Schmidt, M., Kelly, P. F., & Baum, C. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.07.007 · Cited by 36
Gillard, M., Jia, Z., Hou, J. J. C., Song, M., Gray, P. P., Munro, T. P., & Monteiro, M. J. (2014) · Biomacromolecules · doi:10.1021/bm5008376 · Cited by 35
Kremer, L. P. M., Cerrizuela, S., Dehler, S., Stiehl, T., Weinmann, J., Abendroth, H., Kleber, S., Laure, A., Andari, J. E., Anders, S., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.07.001 · Cited by 35
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
A novel hTERT promoter–driven E1A therapeutic for ovarian cancer
Xie, X., Hsu, J. L., Choi, M. G., Xia, W., Yamaguchi, H., Chen, C., Trinh, B. Q., Lü, Z., Ueno, N. T., Wolf, J. K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0056 · Cited by 35
“Use of nonviral vectors would, however, be ideal because viral vector–mediated gene therapy can produce serious complications (49, 50).”
BackgroundLira, R. B., Seabra, M. A. B. L., Matos, A. L. L., Vasconcelos, J. V., Bezerra, D. P., de Paula, E., Santos, B. S., & Fontes, A. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20245c · Cited by 35
Kim, T. S., Choi, H., Ryu, B., Gang, G.-T., Kim, S. U., Koo, D., Kim, J., Han, J. H., Park, C. K., Her, S., et al. (2009) · Theriogenology · doi:10.1016/j.theriogenology.2009.07.028 · Cited by 35
“[51] on the comparative analysis of the main viral vector types stated that LV should integrate into a vector genome form and facilitate transgene expression.”
BackgroundSoftware-aided automatic laser optoporation and transfection of cells
Breunig, H. G., Uchugonova, A., Batista, A., & König, K. (2015) · Scientific Reports · doi:10.1038/srep11185 · Cited by 35
Raisin, S., Morille, M., Bony, C., Noël, D., Devoisselle, J., & Belamie, E. (2017) · Biomaterials Science · doi:10.1039/c7bm00384f · Cited by 35
Sun, Y., Lv, X., Ding, P., Wang, L., Sun, Y., Li, S., Zhang, H., & Gao, Z. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.06.059 · Cited by 35
He, Y., Wang, M., Li, X., Yu, T., & Gao, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120046 · Cited by 35
Effect of medium sugar source on the production of retroviral vectors for gene therapy
Coroadinha, A. S., Ribeiro, J. D., Roldão, A., Cruz, P. E., Alves, P. M., Merten, O.-W., & Carrondo, M. J. T. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20778 · Cited by 35
“Oncoretrovirus vectors derived from Moloney murine leukemia virus (MoMLV) were the first class of viral vectors developed for gene therapy and have been widely used in clinical trials, in particular as vectors of choice for ex vivo transduction of hematopoietic stem cells (Thomas et al., 2003).”
BackgroundIntrathecal Injection of Naked Plasmid DNA Provides Long-term Expression of Secreted Proteins
Hughes, T., Langer, S. J., Johnson, K. W., Chavez, R. A., Watkins, L. R., Milligan, E. D., & Leinwand, L. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.230 · Cited by 35
Multifunctional Non‐Viral Delivery Systems Based on Conjugated Polymers
Yang, G., Lv, F., Wang, B., Liu, L., Yang, Q., & Wang, S. (2012) · Macromolecular Bioscience · doi:10.1002/mabi.201200267 · Cited by 35
Peñuelas, I., Boán, J. F., Martí-Climent, J. M., Sangro, B., Mazzolini, G. D., Prìeto, J., & Richter, J. Á. (2004) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2004.04.004 · Cited by 35
Cho, S. K., & Kwon, Y. J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.027 · Cited by 34
Chitosan for DNA and gene therapy
Layek, B., & Singh, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100228-5.00008-0 · Cited by 34
Recent challenges and advances in genetically-engineered cell therapy
Yong, S., Chung, J. Y., Song, Y., & Kim, Y. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0381-1 · Cited by 34
“The self-renewing nature of HSCs must be stably introduced into the cells either by vector mediated delivery or in situ gene editing (Thomas et al. 2003).”
BackgroundGene therapies for inherited skin disorders
Abdul‐Wahab, A., Qasim, W., & McGrath, J. A. (2014) · Seminars in Cutaneous Medicine and Surgery · doi:10.12788/j.sder.0085 · Cited by 34
Jack of many trades: Multifaceted role of neuropilins in pancreatic cancer
Matkar, P. N., Jong, E. D., Ariyagunarajah, R., Prud’homme, G. J., Singh, K. K., & Leong-Poi, H. M. (2018) · Cancer Medicine · doi:10.1002/cam4.1715 · Cited by 34
Engineering lymphocytes with RNAi
Ramishetti, S., & Peer, D. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.002 · Cited by 34
Bioengineered smart bacterial carriers for combinational targeted therapy of solid tumours
Alizadeh, S., Esmaeili, A., Barzegari, A., Rafi, M. A., & Omidi, Y. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1737087 · Cited by 34
Current and emerging pharmacotherapy for Gaucher disease in pediatric populations
Sam, R., Ryan, E., Daykin, E. C., & Sidransky, E. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1902989 · Cited by 34
“to whether they integrate into the host genome or persist as extrachromosomal episomes [122].”
BackgroundHuman gene therapy: A scientometric analysis
Zhou, W., & Wang, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111510 · Cited by 34
Xie, X., Ji, J., Chen, X., Xu, W., Chen, H., Zhu, S., Wu, J., Wu, Y., Sun, Y., Sai, W., et al. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02705-7 · Cited by 34
Expanding CAR-T cell immunotherapy horizons through microfluidics
Kim, H., Kim, S., Lim, H., & Chung, A. J. (2024) · Lab on a Chip · doi:10.1039/d3lc00622k · Cited by 34
Cationic nucleolipids as efficient siRNA carriers
Yang, H. W., Yi, J. W., Bang, E., Jeon, E. M., & Kim, B. H. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00580k · Cited by 34
Advances with the use of bio-inspired vectors towards creation of artificial viruses
McCarthy, H. O., Wang, Y., Mangipudi, S. S., & Hatefi, A. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903579989 · Cited by 34
“These viruses have the tendency to retain the therapeutic DNA as an independent extrachromosomal episome [3].”
BackgroundInfluentialPEGylated bioreducible poly(amido amine)s for non-viral gene delivery
Lin, C., & Engbersen, J. F. J. (2011) · Materials Science and Engineering C · doi:10.1016/j.msec.2011.04.017 · Cited by 34
Zhang, L., ZHANG, T.-T., Wang, L., Shao, S., Chen, Z., & Zhang, Z. (2014) · Gene Therapy · doi:10.1038/gt.2014.50 · Cited by 34
Lentiviral Vector-Mediated RNA Silencing in the Central Nervous System
Hutson, T. H., Foster, E., Moon, L. D. F., & Yáñez‐Muñoz, R. J. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.016 · Cited by 35
“First, they have been demonstrated to efficiently transduce postmitotic cells including CNS neurons in vitro and in vivo (Naldini et al., 1996a,b; Blomer et al., 1997; Thomas et al., 2003; Naldini, 2011) and have been effective in several animal models of CNS diseases (Ralph et al.”
InfluentialYen, J. S., Ying, H., Wang, H., Yin, L., Uckun, F. M., & Cheng, J. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00393 · Cited by 34
Cheng, H., Fan, X., Wu, C., Wang, X., Wang, L., Loh, X. J., Li, Z., & Wu, Y. (2018) · Macromolecular Rapid Communications · doi:10.1002/marc.201800207 · Cited by 34
Progress in the application of CRISPR: From gene to base editing
Wu, W., Yang, Y., & Lei, H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21537 · Cited by 34
“However, the capacity is one of the major limitation because the fusion proteins that are too large to be expressed using AAV vectors.(122) To deliver exogenous nucleic acids such as acids such as DNA to mammalian cells, these limitations can be addressed by changing the size of nucleases or using other synthetic nonv…”
BackgroundWarriner, L. W., Duke, J. R., Pack, D. W., & DeRouchey, J. E. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b01248 · Cited by 34
Song, Z., Liang, X., Wang, Y., Han, H., Yang, J., Fang, X., & Li, Q. (2019) · Biomaterials Science · doi:10.1039/c8bm01385c · Cited by 34
Assessment of optimal transduction of primary human skin keratinocytes by viral vectors
Gagnoux-Palacios, L., Hervouet, C., Spirito, F., Roques, S., Mezzina, M., Danos, O., & Meneguzzi, G. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.768 · Cited by 34
“At present, viral vectors constitute the most efficient tool for efficient gene transfer into cells, and efforts have been made to improve efficacy, specific cell targeting and safety [12].”
BackgroundYan, Y., Du, J., Chen, T., Yi, M., Li, M., Wang, S., Li, C. M., & Hong, Y. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.04.015 · Cited by 34
Gene delivery to dendritic cells by orally administered recombinant Saccharomyces cerevisiae in mice
Kiflmariam, M. G., Yang, H., & Zhang, Z. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.048 · Cited by 34
Genetically engineered Sertoli cells are able to survive allogeneic transplantation
Dufour, J. M., Hemendinger, R. A., Halberstadt, C. R., Gores, P. F., Emerich, D. F., Korbutt, G. S., & Rajotte, R. V. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302218 · Cited by 34
Kim, H. T., Zaffagnini, S., Mizuno, S., Abelow, S. P., & Safran, M. R. (2006) · Journal of Orthopaedic and Sports Physical Therapy · doi:10.2519/jospt.2006.2284 · Cited by 34
Naik, S., Shreya, A. B., Raychaudhuri, R., Pandey, A., Lewis, S. A., Hazarika, M., Bhandary, S. V., Rao, B. S. S., & Mutalik, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118712 · Cited by 33
Wu, Y., Chen, J., & Jong, Y. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01123-z · Cited by 34
“…amenable as a platform for the production of recombinant vectors used in gene therapy, such as their lack of pathogenicity, defective replication, non-genome-integrating behavior, ability to establish long-term transgenic expression, and multiple serotypes permitting liver targeting [20, 22–24].”
Progress in Pseudotyping Lentiviral Vectors Towards Cell-Specific Gene Delivery In Vivo
Arduini, A., Katiyar, H., & Liang, C. (2025) · Viruses · doi:10.3390/v17060802 · Cited by 33
Bioreducible poly(amido amine)s with different branching degrees as gene delivery vectors
Zhang, B., Ma, X., Murdoch, W. J., Radosz, M., & Shen, Y. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24772 · Cited by 33
“While the clinical applications of viral vectors are largely limited due to their safety issues (Cho and Kwon, 2012; Thomas et al., 2003), nonviral carriers exhibit unique advantages such as low toxicity, biodegradability, tissue/tumor targeting, and applicable scale-up to production (Kibria et…”
Al-Dulaymi, M., Chitanda, J. M., Mohammed‐Saeid, W., Araghi, H. Y., Verrall, R. E., Grochulski, P., & Badea, I. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9906-1 · Cited by 33
Zhu, J., Zhang, M., Ding, X., Qiu, W., Yu, W., Feng, J. X., & Zhang, X. (2018) · Advanced Materials · doi:10.1002/adma.201707459 · Cited by 33
Cheung, W. Y., Hovey, O. F. J., Gobin, J., Muradia, G., Mehic, J., Westwood, C., & Lavoie, J. R. (2018) · Stem Cells International · doi:10.1155/2018/1310904 · Cited by 34
Zhang, X., Lin, Z., Yang, J., Liu, G., Hu, Z., Huang, H., Li, X., Liu, Q., Ma, M., Xu, Z., et al. (2021) · Nanomaterials · doi:10.3390/nano11092312 · Cited by 33
“In recent years, due to the potential bio-risk associated with viral vectors, such as immune responses and insertional mutagenesis, nonviral vectors have gained a great deal of attention [18,19].”
BackgroundStrauss, B. E., & Costanzi-Strauss, E. (2007) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006005000085 · Cited by 33
Reichenbach, P., Attianese, G. M. P. G., Ouchen, K., Cribioli, E., Triboulet, M. M., Ash, S., Saillard, M., de Silly, R. V., Coukos, G., & Irving, M. B. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01013-5 · Cited by 33
Wang, Z., Zhang, Y., Wu, L., Chen, J., Xie, S., He, J., Zhang, Q., Chen, H., Chen, F., Liu, Y., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202307656 · Cited by 33
Jha, S. K., Imran, M., Jha, L. A., Hasan, N., Panthi, V. K., Paudel, K. R., Almalki, W. H., Mohammed, Y., & Kesharwani, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116823 · Cited by 33
Electroactive nanoinjection platform for intracellular delivery and gene silencing
Shokouhi, A., Chen, Y., Yoh, H. Z., Murayama, T., Suu, K., Morikawa, Y., Brenker, J., Alan, T., Voelcker, N. H., & Elnathan, R. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02056-1 · Cited by 33
“Several approaches have been developed to increase the cell membrane’s permeability—either by exposing it to chemical agents [50, 51], viral vectors [52, 53], or cell-penetrating peptides [54, 55] (carrier-mediated), or by applying direct physical stress to the membrane…”
BackgroundSpotlight on movement disorders: What optogenetics has to offer
Rossi, M. A., Calakos, N., & Yin, H. H. (2015) · Movement Disorders · doi:10.1002/mds.26184 · Cited by 33
“Viral delivery of exogenous genes has already been clinically tested in PD patients,(44,45) but the long-term safety and viability of viral delivery of exogenous genes is largely unknown.(46,47) Viral transfection of”
BackgroundMuLV IN mutants responsive to HDAC inhibitors enhance transcription from unintegrated retroviral DNA
Schneider, W. M., Wu, D.-T., Amin, V., Aiyer, S., & Roth, M. J. (2012) · Virology · doi:10.1016/j.virol.2012.01.034 · Cited by 33
“Integration and alteration of the host DNA potentiates the risk of insertional mutagenesis and oncogene activation (Thomas et al., 2003).”
BackgroundRNA interference-based therapeutics for shrimp viral diseases
Krishnan, P., Gireesh-Babu, P., Rajendran, K., & Chaudhari, A. (2009) · Diseases of Aquatic Organisms · doi:10.3354/dao02126 · Cited by 33
“Though viral vectors are recognized as efficient delivery systems for nucleic acids, their use in shrimps is limited as they induce toxic immune responses (Kay & Nakai 2003, Thomas et al. 2003) and run the risk of being randomly integrated into the host genome (Kay et al. 2001).”
BackgroundGenetically engineered immune privileged Sertoli cells: A new road to cell based gene therapy
Kaur, G., Long, C. R., & Dufour, J. M. (2012) · Spermatogenesis · doi:10.4161/spmg.19119 · Cited by 33
“Besides an immune reaction, another major concern with the use of integrating viral vectors is insertional mutagenesis.(59) Although genomic integration is an essential feature to obtain stable expression of the transgene, it is a double-edged sword that can also lead to insertional mutagenesis and potentially cancer…”
BackgroundInfluentialRNA Interference-Based Therapeutics: Molecular Platforms for Infectious Diseases
Dyawanapelly, S., Ghodke, S., Vishwanathan, R., Dandekar, P. P., & Jain, R. D. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.1929 · Cited by 33
Marcélis, L., Moucheron, C., & Mesmaeker, A. K. (2013) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2012.0131 · Cited by 33
Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems
Youngren-Ortiz, S. R., Gandhi, N. S., España‐Serrano, L., & Chougule, M. B. (2016) · KONA Powder and Particle Journal · doi:10.14356/kona.2017005 · Cited by 33
Toxicological exploration of peptide-based cationic liposomes in siRNA delivery
Zhu, Y., Meng, Y., Zhao, Y., Zhu, J., Xu, H., Zhang, E. X., Shi, L., Du, L., Liu, G., Zhang, C., et al. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.03.052 · Cited by 33
Wound Healing Enhancement: Electroporation to Address a Classic Problem of Military Medicine
Ferguson, M. W. J., Byrnes, C. K., Sun, L. L., Marti, G. P., Bonde, P., Duncan, M. D., & Harmon, J. W. (2005) · World Journal of Surgery · doi:10.1007/s00268-004-2062-2 · Cited by 33
“concerns about its safety and potential pathogenicity [13].”
BackgroundESCRT Requirements for Murine Leukemia Virus Release
Bartusch, C., & Prange, R. (2016) · Viruses · doi:10.3390/v8040103 · Cited by 33
“Given that MLV is an important model system to study the usefulness of retrovirus vectors in gene-transfer trials [29], the elucidation of the budding pathways of its particle types may also be instrumental.”
BackgroundChen, N. K. F., Wong, J. S., Kee, I. H. C., Lai, S. H., Thng, C. H., Ng, W. H., Ng, R. T. H., Tan, S., Lee, S. Y., Tan, M. E. H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001734 · Cited by 33
“Moreover, transduced cells that express viral proteins are targets for host immunological destruction–a cause of transient transgene expression [10].”
Engineering chromosomes for delivery of therapeutic genes
Irvine, D. V., Shaw, M. L., Choo, K. H. A., & Saffery, R. (2005) · Trends in biotechnology · doi:10.1016/j.tibtech.2005.10.001 · Cited by 33
Hanafy, B. I., Munson, M. J., Soundararajan, R., Pereira, S. G. T., Gallud, A., Sanaullah, S. M., Carlesso, G., & Mazza, M. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500383 · Cited by 32
Hosseinpour, S., Cao, Y., Liu, J., Xu, C., & Walsh, L. J. (2021) · Journal of Materials Chemistry B · doi:10.1039/d0tb02756a · Cited by 32
Biosafety assessment of delivery systems for clinical nucleic acid therapeutics
Li, Z., Zhang, L., Jiang, K., Zhang, Y., Liu, Y., Hu, G., & Song, J. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2022.03.003 · Cited by 32
Gene Therapy for Inherited Hearing Loss: Updates and Remaining Challenges
Hahn, R., & Avraham, K. B. (2023) · Audiology Research · doi:10.3390/audiolres13060083 · Cited by 33
“A major advantage of AdV is its large packaging capacity, with a range of 26 kb to 45 kb, depending on the serotype [92,93].”
BackgroundSalomone, F., Cardarelli, F., Signore, G., Boccardi, C., & Beltram, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070108 · Cited by 32
“genome, in the case of retroviruses [4,5].”
Efficient Gene Delivery by EGF-LipoplexesIn VitroandIn Vivo
Buñuales, M., Düzgüneş, N., Zalba, S., Garrido, M. J., & de Ilarduya, C. T. (2010) · Nanomedicine · doi:10.2217/nnm.10.100 · Cited by 32
Lin, P., Liu, M., Xue, Y., Huang, S., & Zhuo, R. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.005 · Cited by 32
“concerns related to the immunogenicity of some viral carriers and random integration of viral genes into the host genome [11].”
BackgroundEnhanced plasmid DNA delivery using anionic LPDII by listeriolysin O incorporation
Lorenzi, G. L., & Lee, K. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.750 · Cited by 32
“While some gene delivery technologies, including both viral and non-viral vectors such as cationic liposomes and polymer-based delivery systems, have already shown great promise, each system has unique limitations [1–5].”
BackgroundEngineering Stem Cells for Biomedical Applications
Yin, P. T., Han, E. X., & Lee, K. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400842 · Cited by 33
Glud, A. N., Hedegaard, C., Nielsen, M. S., Søorensen, J. C., Bendixen, C., Jensen, P. H., Mogensen, P., Larsen, K., & Bjarkam, C. R. (2011) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2011-1867 · Cited by 34
“In addition, AAV also have a low packaging capacity (Verma and Somia 1997, Davidson and Breakefield 2003, Thomas et al. 2003).”
BackgroundNanoparticle-based delivery for the treatment of inner ear disorders
Pyykkö, I. V., Zou, J., Zhang, W., & Zhang, Y. (2011) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0b013e32834aa3a8 · Cited by 32
Cottle, R. N., Lee, C. M., Archer, D. R., & Bao, G. (2015) · Scientific Reports · doi:10.1038/srep16031 · Cited by 32
Núñez-Toldrà, R., Dosta, P., Montori, S., Ramos, V., Atari, M., & Borrós, S. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.01.077 · Cited by 32
“In addition, viral vectors show limited nucleic acid packaging and difficulty scale-up production [21,22].”
BackgroundParis, J. J., Ahluwalia, J. S., Cummings, B., Moreland, M. P., & Wilkinson, D. J. C. (2017) · Journal of Perinatology · doi:10.1038/jp.2017.138 · Cited by 32
Modified Exosomes Reduce Apoptosis and Ameliorate Neural Deficits Induced by Traumatic Brain Injury
Wang, B., & Han, S. (2019) · ASAIO Journal · doi:10.1097/mat.0000000000000810 · Cited by 31
Nanocarriers in Effective Pulmonary Delivery of siRNA: Current Approaches and Challenges
Bardoliwala, D., Patel, V., Javia, A., Ghosh, S., Patel, A., & Misra, A. R. (2019) · Therapeutic Delivery · doi:10.4155/tde-2019-0012 · Cited by 32
Non-viral gene delivery systems: hurdles for bench-to-bedside transformation
Helal, N. A., Osami, A., Helmy, A., McDonald, T., Shaaban, L. A., & Nounou, M. I. (2017) · Die Pharmazie · doi:10.31083/ph.2017.7092 · Cited by 32
Engineering Bioinspired Nanomedicines to Mitigate the Resistance to Cancer Immunotherapy
Ye, J., Hou, B., Saeed, M., Xu, Z., & Yu, H. (2022) · Accounts of Materials Research · doi:10.1021/accountsmr.2c00042 · Cited by 32
Wang, J., Xian, X., Huang, W. Y., Chen, L., Wu, L., Zhu, Y., Fan, J., Ross, C. J., Hayden, M. R., & Liu, C. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000249683.80414.d9 · Cited by 32
Radecke, F., Radecke, S. M., & Schwarz, K. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.613 · Cited by 32
Li, W., Chen, L., Huang, Z., Wu, X., Zhang, Y., Hu, Q., & Wang, Y. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c1ob05886j · Cited by 31
Zheng, N., Song, Z., Yang, J., Liu, Y., Li, F., Cheng, J., & Yin, L. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.001 · Cited by 31
“While viral vectors afford high transfection efficiencies, they often suffer from serious clinical risks such as oncogenicity, immunogenicity, and insertional mutagenesis [9].”
BackgroundLü, Y., Tang, L., Zhang, M., & Liu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896958 · Cited by 31
“Tumor retroviral vectors are the first kind of viral vectors developed, and they are the preferred vectors for in vitro transfection of regenerated hematopoietic stem cells (77).”
Background
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.